Arcus Biosciences, Inc. (NYSE: RCUS)

Arcus Biosciences, Inc. is a late clinical stage biopharmaceutical company focused on discovering and developing differentiated small molecule and antibody therapies for patients with cancer and inflammatory and autoimmune diseases. The company leverages its internal discovery capabilities to advance a pipeline that includes hypoxia inducible factor 2α inhibitor casdatifan, CD73 inhibitor vemliclustat, anti TIGIT antibody domvanalimab, and anti PD 1 antibody zimberelimab, alongside earlier stage inflammation programs targeting MRGPRX2, TNF, CCR6, CD89, and CD40 ligand.

Arcus Biosciences generates revenue primarily through collaboration and licensing agreements that provide upfront payments, milestone reimbursements, and potential royalties on future product sales. Under its agreements with Gilead, the company receives funding for co development of domvanalimab, vemliclustat, and zimberelimab and is eligible for milestone payments and tiered royalties on sales outside the United States. The Taiho partnership provides option exercise payments, clinical and regulatory milestones, and royalties on net sales in Japan and other Asian countries for casdatifan and other programs.

The company operates through the following segments.

• Reportable Segment: This segment encompasses the company’s research, development and commercialization activities for cancer and inflammatory autoimmune disease therapies, including the advancement of casdatifan, vemliclustat, domvanalimab, zimberelimab, and early stage inflammation programs through preclinical and clinical stages.

Arcus Biosciences operates in a highly competitive biopharmaceutical landscape where it faces large multinational companies such as AstraZeneca, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, Regeneron, and Roche/Genentech in oncology, and competitors like Abbvie, Amgen, Sanofi, and Regeneron in the inflammatory and autoimmune space. The company’s competitive advantages stem from its proprietary small molecule discovery platform, which enables the creation of differentiated molecules with improved pharmacokinetics, and its strategic collaborations that provide financial support and validation of its pipeline.

The company’s current customers are primarily its collaboration partners, including Gilead and Taiho, which fund research and development through milestone and royalty arrangements. In the future, upon regulatory approval, Arcus Biosciences expects to serve patients, healthcare providers, and payors such as hospitals, clinics, and insurance companies for its therapeutic products.